MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation

NASDAQ:MLAB • US59064R1095

Current stock price

103.18 USD
+1.53 (+1.51%)
Last:

This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MLAB Profitability Analysis

1.1 Basic Checks

  • In the past year MLAB was profitable.
  • In the past year MLAB had a positive cash flow from operations.
  • In multiple years MLAB reported negative net income over the last 5 years.
  • MLAB had a positive operating cash flow in each of the past 5 years.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • MLAB's Return On Assets of 0.86% is fine compared to the rest of the industry. MLAB outperforms 67.86% of its industry peers.
  • With a decent Return On Equity value of 2.00%, MLAB is doing good in the industry, outperforming 69.64% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.58%, MLAB is in the better half of the industry, outperforming 66.07% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 11.80%.
  • The last Return On Invested Capital (3.58%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • MLAB's Profit Margin of 1.51% is fine compared to the rest of the industry. MLAB outperforms 67.86% of its industry peers.
  • Looking at the Operating Margin, with a value of 6.96%, MLAB is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
  • MLAB's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 62.40%, MLAB belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
  • MLAB's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MLAB Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
  • The number of shares outstanding for MLAB has been increased compared to 1 year ago.
  • Compared to 5 years ago, MLAB has more shares outstanding
  • MLAB has a better debt/assets ratio than last year.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.62, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
  • MLAB has a Altman-Z score (1.62) which is in line with its industry peers.
  • The Debt to FCF ratio of MLAB is 4.41, which is a neutral value as it means it would take MLAB, 4.41 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.41, MLAB is in the better half of the industry, outperforming 73.21% of the companies in the same industry.
  • MLAB has a Debt/Equity ratio of 0.86. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
  • The Debt to Equity ratio of MLAB (0.86) is worse than 76.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.62
ROIC/WACC0.33
WACC10.72%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • MLAB has a Current ratio of 1.94. This is in the lower half of the industry: MLAB underperforms 64.29% of its industry peers.
  • A Quick Ratio of 1.45 indicates that MLAB should not have too much problems paying its short term obligations.
  • MLAB's Quick ratio of 1.45 is on the low side compared to the rest of the industry. MLAB is outperformed by 66.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MLAB Growth Analysis

3.1 Past

  • MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.40%.
  • Measured over the past years, MLAB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -39.16% on average per year.
  • Looking at the last year, MLAB shows a small growth in Revenue. The Revenue has grown by 4.12% in the last year.
  • Measured over the past years, MLAB shows a quite strong growth in Revenue. The Revenue has been growing by 15.41% on average per year.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 247.51% on average per year.
  • MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.11% yearly.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. MLAB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 161.22, which means the current valuation is very expensive for MLAB.
  • MLAB's Price/Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 27.66, MLAB is valued quite expensively.
  • With a Price/Forward Earnings ratio of 71.49, MLAB can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (38.00), we can say MLAB is valued expensively.
Industry RankSector Rank
PE 161.22
Fwd PE 71.49
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MLAB is valued cheaper than 80.36% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 89.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.11
EV/EBITDA 16.53
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • MLAB's earnings are expected to grow with 247.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MLAB Dividend Analysis

5.1 Amount

  • MLAB has a yearly dividend return of 0.65%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.11, MLAB pays a better dividend. On top of this MLAB pays more dividend than 96.43% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, MLAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.65%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
  • MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years22
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • MLAB pays out 93.97% of its income as dividend. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MLAB Fundamentals: All Metrics, Ratios and Statistics

MESA LABORATORIES INC

NASDAQ:MLAB (4/22/2026, 10:14:17 AM)

103.18

+1.53 (+1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners93.82%
Inst Owner Change0.06%
Ins Owners2.86%
Ins Owner Change3.15%
Market Cap569.55M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (3.3%)
Short Float %4.23%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield 0.65%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years22
Ex-Date05-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)0%
PT rev (3m)5.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)0%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 161.22
Fwd PE 71.49
P/S 2.3
P/FCF 15.11
P/OCF 13.71
P/B 3.05
P/tB N/A
EV/EBITDA 16.53
EPS(TTM)0.64
EY0.62%
EPS(NY)1.44
Fwd EY1.4%
FCF(TTM)6.83
FCFY6.62%
OCF(TTM)7.52
OCFY7.29%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.05
PEG (5Y)N/A
Graham Number22.0685 (-78.61%)
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.62
F-Score6
WACC10.72%
ROIC/WACC0.33
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


Can you provide the profitability details for MESA LABORATORIES INC?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MLAB stock?

The Price/Earnings (PE) ratio for MESA LABORATORIES INC (MLAB) is 161.22 and the Price/Book (PB) ratio is 3.05.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.